Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. 2seventy bio, Inc.
  6. News
  7. Summary
    TSVT   US9013841070

2SEVENTY BIO, INC.

(TSVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

2Seventy Bio Working With Novo Nordisk to Develop Potential Gene-Editing Treatment for Hemophilia A

01/06/2022 | 07:40am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
2SEVENTY BIO, INC. 3.61% 11.78 Delayed Quote.-55.64%
NOVO NORDISK A/S -1.62% 730.9 Delayed Quote.1.07%
All news about 2SEVENTY BIO, INC.
05/17Morgan Stanley Adjusts 2seventy bio's Price Target to $31 from $36, Keeps Overweight Ra..
MT
05/122SEVENTY BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
05/122seventy bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/122seventy bio Reports First Quarter Financial Results and Recent Operational Progress
BU
05/12Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $8.4M
MT
05/02Goldman Sachs Starts 2seventy Bio at Buy With $26 Price Target
MT
04/292SEVENTY BIO, INC. : Other Events (form 8-K)
AQ
04/292seventy bio, Inc. Enters into the First Amendment to the License Agreement
CI
04/292Seventy Bio Files for Potential Secondary Offering
MT
04/082SEVENTY BIO : Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting ..
PU
More news
Analyst Recommendations on 2SEVENTY BIO, INC.
More recommendations
Financials (USD)
Sales 2022 81,3 M - -
Net income 2022 -240 M - -
Net cash 2022 213 M - -
P/E ratio 2022 -1,44x
Yield 2022 -
Capitalization 428 M 428 M -
EV / Sales 2022 2,64x
EV / Sales 2023 1,33x
Nbr of Employees 437
Free-Float 98,5%
Chart 2SEVENTY BIO, INC.
Duration : Period :
2seventy bio, Inc. Technical Analysis Chart | TSVT | US9013841070 | MarketScreener
Technical analysis trends 2SEVENTY BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 11,37 $
Average target price 33,20 $
Spread / Average Target 192%
EPS Revisions
Managers and Directors
Nick Leschly President & Director
William Denise Baird Chief Financial & Accounting Officer
Daniel S. Lynch Chairman
Philip D. Gregory Chief Scientific Officer
Steven H. Bernstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
2SEVENTY BIO, INC.-55.64%428
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524